Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Sigma Labs Inc. (NASDAQ: SGLB) Leveraging Revolutionary Quality-Assurance Technology to Assist Aerospace 3D-Printing Market

Sigma Labs (NASDAQ: SGLB), a leading developer of quality-control software for the commercial 3D-printing industry, is set to assist aerospace manufacturers in beating their 3D quality manufacturing concerns. An article discussing the company reads, “The global aerospace 3D-printing market was estimated at $1.4 billion in 2018, projected to reach $6.8 billion by 2026 with an expected CAGR in excess of 22% during the forecast period. The airline and spacecraft segment is expected to lead the aerospace 3D-printing market due to the need for low-volume, low-weight parts that can be manufactured using 3D-printing technologies, which reduces supply chain constraints, minimizes warehouse space and lowers waste materials compared to traditional manufacturing processes (http://ibn.fm/cWh1C). . . . As the industry is challenged by environmental restrictions, high manufacturing cost and a competitive market environment, 3D metal-components manufacturing offers a unique solution to help overcome much of these challenges.”

To view the full article, visit http://ibn.fm/jt8vA

About Sigma Labs Inc.

Sigma Labs is a leading provider of quality-assurance software to the commercial, 3D-printing industry under the PrintRite3D(R) brand. Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time, computer-aided inspection (CAI) solutions known as PrintRite3D for 3D advanced-manufacturing technologies. Sigma Labs’ advanced, computer-aided, software product revolutionizes commercial additive manufacturing, enabling nondestructive quality assurance mid-production and uniquely allowing errors to be corrected in real time. For more information, visit the company’s website at www.SigmaLabsInc.com.

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Sigma Labs Inc. SGLB | Leave a comment

Interpace Biosciences (NASDAQ: IDXG) Growth Capacity Aided by $20 Million Investment Agreement with Major Capital Partners

  • Leading private equity firms 1315 Capital and Ampersand Capital Partners’ recent investment agreement with Interpace signal a “clear vote of confidence”
  • Company’s business units, Interpace Diagnostics and Interpace Pharma Solutions, support the biotech and pharmaceutical sectors as they seek to improve early cancer diagnosis and promote increasingly effective therapies
  • Life sciences industry forecast to reach $33.2 billion by 2024, experiencing an 11.5% CAGR over 5-year period

Interpace Biosciences (NASDAQ: IDXG), an evolving leader in the life sciences industry, recently entered into a $20 million investment agreement with two leading private equity firms investing in laboratory services (http://ibn.fm/G8cUU). The Series B Preferred stock investment consisting of $19 million and $1 million from 1315 Capital and Ampersand Capital Partners, respectively, will be a boon to IDXG’s growing power in an industry anticipated to reach $33.2 billion by 2024 – an increase from its $19.3 billion in 2019. The life sciences industry is forecast to experience a CAGR of 11.5% over the period (http://ibn.fm/H1lmI).

“We believe 1315 Capital will be, and Ampersand [a current investor] will continue to be, great partners for Interpace,” Interpace president and CEO Jack Stover stated in a news release. “This is a clear vote of confidence in Interpace and its diagnostic and pharma solutions businesses.”

In addition to the investment agreement, Interpace also announced its intention to effect a one-for-ten reverse stock split effective coincident with the former’s closing. The reverse stock split is meant to satisfy the Nasdaq Capital Market’s minimum bid price requirement by increasing the per share trading price of IDXG’s common stock. “We believe this proposed change in capital structure can benefit our stockholders and make our stock more attractive to institutional and other investors,” Stover noted.

Having assisted physicians in the diagnosis and treatment of over 75,000 patients, Interpace Biosciences has made contributions to some of the pharmaceutical and biotech industry’s most critical clinical trials (http://ibn.fm/ENyPi). Its business arms, Interpace Diagnostics™ and Interpace Pharma Solutions™, support the biomedical and oncological industries by empowering clinicians with complex molecular analysis data. This data helps enhance the efficacy of early cancer diagnosis and treatment, as well as supporting the development of targeted therapeutics.

Business unit Interpace Diagnostics™, focused on “resolving diagnostic uncertainty,” offers evidence-based, clinically beneficial molecular diagnostic tests and pathology services (http://ibn.fm/T04KG). Its offerings include reputable tests like PancraGen®, ThyGeNext®, ThyraMir®, RespriDX® and BarreGen®. The company’s tests assist in risk stratification of patient samples for a multitude of cancers, including thyroid, pancreatic and lung, among others. Results gleaned from these tests are used by physicians to make better, more effective treatment decisions that more accurately target each individual patient – determining whether patients are better suited for surgery or active surveillance. These recommendations have the potential to help health care professionals differentiate between potentially malignant cells and benign ones, thus saving patients from risky, expensive surgeries that are frequently unnecessary.

Alternatively, IDXG’s Interpace Pharma Solutions™ business unit works hand-in-glove with biopharmaceutical companies by providing lab testing, data management, project management and biorepository services (http://ibn.fm/joRK6). By utilizing Interpace Pharma Solutions’ scientific, medical and expert knowledge, biopharma and diagnostic clients are able to effectively integrate pharmacogenomics – the study of how genes affect a person’s response to drugs – into their drug development and clinical trial programs. Interpace Pharma Solutions’ platform generates logistical reports comprised of biomarker analysis, anatomic pathology, cytogenetics and customized molecular technologies (http://ibn.fm/619vG). As medicine personalized through the lens of genetics was recently referenced as one of the top trends in the life sciences industry (http://ibn.fm/KGwPA), Interpace Biosciences appears well-positioned to stay abreast of the dynamic industry and is an attractive option for pharmaceutical and biotech companies conducting or aiding in oncology-focused clinical trials.

Globally, the molecular diagnostics market is estimated to experience a CAGR of 8.7% during the forecast period from 2018 to 2024 (http://ibn.fm/6hNeA). With a comprehensive testing portfolio, Interpace Biosciences presents a convincing opportunity for investors looking to benefit from the global community’s growing reliance on personalized medicine.

For more information, visit the company’s website at www.Interpace.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Interpace Biosciences IDXG | Leave a comment

MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Prices $8M Common Stock Offering At-The-Market

Genprex (NASDAQ: GNPX), a clinical stage gene therapy company developing a new and potentially life-saving approach to treating some of the world’s most deadly cancers based upon a novel proprietary technology platform, today announced its entry into securities purchase agreements with institutional investors for the purchase and sale of 7,620,000 shares of common stock. According to the update, the offering is priced at-the-market under Nasdaq rules with par value $0.001 per share at an offering price of $1.05 per share, pursuant to a registered direct offering. Gross proceeds will be approximately $8,000,000 before deducting fees and other estimated offering expenses, and the company intends to use the net proceeds to advance its lead clinical programs in non-small cell lung cancer (“NSCLC”) and for working capital and general corporate purposes. Closing of the registered direct offering is expected to occur on or about January 27, 2020, subject to the satisfaction of customary closing conditions.

To view the full press release, visit http://ibn.fm/L5l9n

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform. Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. The company’s lead product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung cancer (“NSCLC”), has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. For more information, please visit the company’s web site at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment

Sigma Labs Inc. (NASDAQ: SGLB) Delivers Proprietary Technology to Solve Quality, Reliability Challenges in 3D Metal-Printing

  • SGLB delivers solutions to additive manufacturing challenges with its proprietary PrintRite 3D technology
  • Sigma Labs allows companies to build, qualify, and certify parts more quickly and at lower cost
  • Before Sigma, no quality metric existed for melt pool monitoring, in situ monitoring, or process quality control that provided in process alerts and solutions

As additive manufacturing – or 3D metal printing – gains traction in the manufacturing world, the problems with the technology have hampered production and stymied large-scale uptake. Sigma Labs Inc. (NASDAQ: SGLB), a leading producer of quality-assurance software for the commercial 3D-printing industry, is committed to providing answers to those problems in the latest version of its proprietary technology.

“For some engineers, 3D printing may be coming on in an unwelcome rush,” stated a recent Engineering.com article, titled ‘7 Issues to Look Out for in Metal 3D Printing’ (http://ibn.fm/WP70j). “Avoiding issues in metal AM still requires a lot of process knowledge and trial and error,” the article states, denoting how critical it is for operators to monitor processes in real-time—a problem for which SGLB’s PrintRite 3D software offers a solution.

In its own article (http://ibn.fm/whFCl), ‘What Is Metal Additive Manufacturing’, Sigma Labs also acknowledges that “the large-scale adoption of direct 3D metal additive manufacturing faces quality and reliability challenges.” Those challenges are outlined in the article as follows:

  • The machines and processes are inherently variable – machine to machine and within machine – causing variation in manufacturing and production consistency.
  • The build process itself has many adjustable inputs that directly affect the ability to create a part and its final quality.
  • The industry has few design rules, monitoring methods or standards for finished products.
  • There is difficulty ensuring consistent, repeatable quality for final production parts.

In what it calls the “Sigma Solution,” Sigma Labs argues that its IPQA™ technology accurately monitors the quality and reliability of additive manufactured parts by ensuring consistent quality control during the manufacturing process. Until now, optical monitoring systems have recorded the manufacturing process but have been unable to deliver actionable in-process information to enable the rescue of parts straying out of specification. Additionally, parts could only be fully quality inspected post-production in costly and time-consuming processes and only after the mistakes were made. Sigma’s real-time melt pool analytics software frees manufacturers to build, qualify and certify parts more quickly and at a much lower cost.

Sigma’s proprietary software reduces the traditional post-production quality assurance inspection process for additive manufacturing; helps ensure the quality of each part; dramatically reduces costs and labor associated with the current approach to certifying AM part quality by “seeing” and analyzing the structure of a 3D-printed part during production; and allows for correction during the manufacturing process.

Sigma Labs was founded in 2010 and has become the go-to, 3D-printing expert for real-time, computer-aided inspection (CAI) solutions. Founded by experts from scientific disciplines that include metallurgy, physics, signal processing, mechanical engineering, optics, software AI and ML, data analytics and visualization, the company has already established credibility within highly demanding industries such as aerospace, defense, biomedicine and transportation. Sigma Labs’ revolutionary technology is set to unleash the powerful forces of 3D metal printing, changing the face of the industry by increasing reliability, lowering quality control costs and enabling serial manufacturing.

For more information, visit the company’s website at www.SigmaLabsInc.com

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Sigma Labs Inc. SGLB | Leave a comment

MissionIRNewsBreaks – Zacks Small-Cap Research Initiates Coverage on Jerrick Media Holdings Inc. (JMDA)

Zacks Small-Cap Research has initiated coverage on Jerrick Media Holdings (OTCQB: JMDA), a holding company that gives technology products the resources and opportunities to make ideas a reality. Among other highlights, the research report provides an outlook and overview of the company, details regarding the industry and competition, a report of the company’s financials, and a valuation. “We believe based on our forecasts and comparable companies, Jerrick Media could be worth $13.00 per share by 2021 based on multiple of 14 times enterprise value to sales using a combination of public and private company comparables,” the Zacks Small-Cap Research analyst states in the report. “This is based on it successfully reaching estimated sales of $9 million in 2021 without any additional equity dilution than forecasted.”

To view the full report, visit http://ibn.fm/2alQV

About Jerrick

Jerrick Media Holdings, Inc. develops technology-based solutions to solve digital problems. Through the combination of design, thought and data analysis, the company builds products that influence a worldwide audience. Jerrick’s flagship product is Vocal, a proprietary long-form digital publishing platform that provides storytelling tools and engaged communities for creators to get discovered and fund their creativity. For more information, visit the company’s website at https://Jerrick.media.

NOTE TO INVESTORS: The latest news and updates relating to JMDA are available in the company’s newsroom at http://ibn.fm/JMDA

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Jerrick Media Holdings Inc. JMDA, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Jerrick Media Holdings Inc. (JMDA) Launches New Challenges Feature on Vocal

Jerrick Media Holdings (OTCQB: JMDA), a holding company that gives technology products the resources and opportunities to make ideas a reality, today announced the launch of Challenges on its proprietary long-form digital publishing platform Vocal. Through friendly competition, Challenges are intended to inspire new brands and creators to join the Vocal community. Multiple Challenges across a range of topics will be offered each month for creators to participate in for the chance to win cash prizes, experiences, and more. “Challenges are the most important product update introduced into Vocal to date, allowing creators to connect with brands in an authentic, non-interruptive way that builds brand love and affinity while simultaneously giving creators more of what they love about Vocal–monetization and discovery,” Vocal founder and Jerrick president Justin Maury stated in the news release.

To view the full press release, visit http://ibn.fm/uDFla

About Jerrick

Jerrick Media Holdings, Inc. develops technology-based solutions to solve digital problems. Through the combination of design, thought and data analysis, the company builds products that influence a worldwide audience. Jerrick’s flagship product is Vocal, a proprietary long-form digital publishing platform that provides storytelling tools and engaged communities for creators to get discovered and fund their creativity. For more information, visit the company’s website at https://Jerrick.media.

NOTE TO INVESTORS: The latest news and updates relating to JMDA are available in the company’s newsroom at http://ibn.fm/JMDA

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Jerrick Media Holdings Inc. JMDA, MissionIRNewsBreaks | Leave a comment

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Inks Licensing Deal with Smokeless Cannadips CBD Product Maker

  • Lexaria Bioscience is a company dedicated to developing effective oral ingestion methods for drug substances that rival the rapid-delivery qualities of more health-dangerous inhaled-drug products.
  • Inhalation is a particularly popular method of using tobacco and cannabis products, despite government warnings about the scientifically established dangers of doing so
  • Lexaria has been boosting its profile and revenue potential through licensing agreements with other companies
  • Lexaria recently announced a licensing agreement with Cannadips CBD-maker The Boldt Runners Corporation
  • The agreement grants Cannadips CBD use of Lexaria’s DehydraTECH IP to improve the speed of its effectiveness and to combat the throat irritation that can accompany use of terpene-rich multi spectrum oils

Drug product consumption innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has announced a trade agreement that continues to advance the company’s revenue-building efforts through licensing its technology to other product manufacturers that can benefit from Lexaria’s DehydraTECH™ oral drug delivery IP.

The agreement announced recently provides Cannadips CBD with exclusive access rights to Lexaria’s technology for the U.S. market for 10 years, granting the ‘Original Smokeless CBD Dip Brand’ Lexaria’s fast-acting, high-absorption technology with options to expand the license to Europe, Mexico, and Canada and to renew the license for an additional five years (http://ibn.fm/8hoPO).

“This combination of superior science from Lexaria and a unique and strong branded proposition that Cannadips offers with its CBD pouch platform is a winning combination We are excited to be developing a category of products with best in class science to provide adult consumers the simple choice of a better product and a better alternative to tobacco and nicotine,” Lexaria board member Brian Quigley, who is also an adviser to The Boldt Runners Corporation (Cannadips), stated in a news release.

Lexaria has made its mission the development of swallowed drug substance consumption methods that approximate the rapid effectiveness of smoking or vaping, for example, while avoiding the dangers such drug inhalation can cause to users’ lungs. Those dangers gained new visibility during the past year as thousands of vape users fell seriously ill or died after inhaling products containing cannabis or nicotine deemed safer than tobacco smokes (http://ibn.fm/TlRbK).

The need for Lexaria’s IP has become evident as drug inhalation has become popular and has remained so despite science’s development of the means to demonstrate the dangers of smoked products, including cancers, on users’ lungs (http://ibn.fm/gVfND). Orally ingested medications and wellness products have in general been slower to act effectively on the user than inhaled substances and may ultimately enter the bloodstream in a more dilute measure than originally intended because of the body’s digestive screening mechanisms.

DehydraTECH has demonstrated its ability to speed its drug substance payloads to the bloodstream at rates much faster than un-enhanced oral ingestion. A new formulation of DehydraTECH has nearly doubled its rate of effectiveness, showing in lab testing that it can deliver cannabidiol (CBD) into the bloodstream at a rate 811 percent higher than generic industry control formulations, carrying 1,937 percent more CBD across the blood-brain barrier than generic industry control formulations (http://ibn.fm/wWvR4).

The body’s natural blood-brain barrier defense system protects our brain tissue from foreign substances, but also proves to be a deterrent for most small-molecule drugs that aim to enhance wellness through the central nervous system.

Cannadips’ American hemp-derived CBD pouches are an ideal product for pairing with DehydraTECH, offering 15 pouches with 10 mg of CBD (and no tobacco) each for oral delivery in tins similar in appearance to chewing tobacco. According to Lexaria’s news release, Cannadips uses terpene-rich multi spectrum oils as base ingredients that can cause some throat irritation. While some other products cut their terpenes to avoid the problem, DehydraTECH allows Cannadips to reduce the throat irritation while maintaining the entourage effect derived from multi-spectrum oils.

The Cannadips brand is being distributed nationally, including through Circle K convenience outlets, and are in about 5,000 stores in the United States with more in Europe.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Lexaria Bioscience Corp. (LXRP) | Leave a comment

Sigma Labs Inc. (NASDAQ: SGLB) to Capitalize on Growth of Large-Scale 3D Printing in 2020

  • Use of large-scale additive manufacturing has doubled in past year
  • SGLB’s revolutionary quality-assurance software offers unique solution to industry’s most significant hurdles to mass production
  • Sigma Labs set to reap lucrative benefits of revolutionary technology that enables 3D metal printing industry to scale production

A new study has revealed a significant increase in the use of large-scale additive manufacturing technology, also called 3D printing. Essentium, a Texas-based innovator in industrial additive-manufacturing platforms and filament materials, released the study and marks 2020 as the year when additive manufacturing at scale transforms manufacturing across a number of sectors, With multiple manufacturers across various sectors poised to embrace 3D printing at scale in 2020, Sigma Labs Inc. (NASDAQ: SGLB) aims to exploit this rapidly growing market opportunity with its revolutionary technology that enables in-process quality assurance of 3D-metal-printed parts. Sigma Labs is at the epicenter of the explosive additive manufacturing market growth as the leading provider of third-party in-process quality-assurance software for the commercial 3D metal printing industry.

With its unparalleled PrintRite3D® software that allows nondestructive quality assurance during the 3D printing of metal parts, Sigma Labs is ideally positioned to support the manufacturing sector in its mission to harness the transformative power of 3D printing in 2020 and beyond. PrintRite3D enables in-process quality control of 3D metal printing, allowing errors to be detected and corrected in real time, thus saving money and time while providing the ability to scale production. By providing the unique quality-assurance solution that the 3D metal printing industry needs in order to enter mainstream manufacturing, SGLB is set to capitalize on the tremendous growth in 3D printing applications across a wide variety of sectors, including aerospace, automotive, biomedical and electronics.

The Essentium study shows that the number of manufacturers using 3D printing for full-scale production has doubled since 2018 – from 21% in 2018 to 40% in 2019 (http://ibn.fm/U5zSE). Essentium surveyed 162 executives from manufacturing companies around the world about their perspectives on trends and challenges of 3D printing applications in manufacturing. The research revealed that although additive manufacturing has been limited by scale, as the technology and leading players are reaching a new level of maturity, a considerable growth in the use of large-scale additive manufacturing is found. The study shows that the number of manufacturers using 3D printing for full-scale production has doubled since 2018 – from 21% in 2018 to 40% in 2019.

The survey reports that the sharp rise in 3D printing adoption at scale is driven by manufacturers’ need to reduce lead times (61% of respondents) and manufacturing costs (58%). Additionally, 59% of respondents expect to benefit from mass customization, while 59% expect to expand speed-to-part production and 51% want to achieve high part performance. Despite this growing enthusiasm for 3D printing, many respondents still face obstacles such as high costs for 3D-printing materials (51%) and hardware (38%), as well as an inability to scale the current 3D printing technology (31%).

According to the study, open ecosystems are expected to be the prevailing format within the industry as technology hurdles surrounding scale, economics, strength and speed of production face away. With these problems mitigated, the future of the industry can allow for 3D printing users and vendors to realize greater control of their innovation, choice in materials, and industrial-scale production at lower costs.

With additive manufacturing at scale now becoming a reality, Sigma Labs constitutes a compelling investment opportunity as one of the primary enablers of 3D metal printing adoption for serial production.

For more information, visit the company’s website at www.SigmaLabsInc.com

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Sigma Labs Inc. SGLB | Leave a comment

SRAX Inc. (NASDAQ: SRAX) Positioned to Satisfy Modern Consumers’ Desire for Data Monetization, Protection

  • In exclusive interview, CEO discusses how SRAX revolutionizes consumer data collection
  • SRAX committed to building the most valuable opted-in data set in the world
  • Company poised to capitalize on surge of multibillion-dollar data monetization market

In an exclusive interview at the LD Micro Main Event 2019, SRAX Inc. (NASDAQ: SRAX) Founder and CEO Christopher Miglino discussed how SRAX has revolutionized consumer data collection through BIGtoken, its proprietary, secure and transparent platform. The platform enables consumers to own and monetize their data as they earn rewards when they opt into the data sharing, as well as each time their data is purchased and each time they bring a new user to the platform.

With 16.4 million users worldwide, and three to five thousand new users joining each day, BIGtoken may be the most valuable opted-in data set in the world, said Miglino during the interview with SNN’s Robert Crafton (http://ibn.fm/LZQPh). Those numbers prove that consumers are looking for ways to receive compensation from marketers for using their data, said Miglino. Users worldwide can sign into the BIGtoken app, available for download on the App Store and Google Play, to see exactly how much they have earned.

The app benefits are mutual, Miglino pointed out, as consumers decide what data is shared, who can buy it and how it’s used, while advertisers gain verified consumer data for targeted marketing. Big brands such as Procter & Gamble and Kraft are purchasing BIGtoken data.

Users join the platform by answering questions about themselves and agreeing to share their information through location checking in or by connecting their social media accounts. Based on data, users are grouped into anonymized advertising groups to which advertisers buy access, enabling users to earn a portion of the revenue from the data sale.

Currently, big social media platforms are experiencing a strong public backlash as consumers demand to keep their data private. In addition, as consumers become increasingly aware of the value of their data, they expect to receive compensation for releasing their information.

As data-savvy consumers argue for more protection, regulations designed to grant that protection are beginning to roll through the United States as well as around the world, catching some social media giants off-guard. State and federal privacy laws such as the California Consumer Privacy Act, which goes into effect this month, are putting control over data back in the hands of the consumer; similar legislature is being adopted in 13 more states as well as across Europe and India. This is increasingly affecting the way that marketers can reach current and potential customers. Thanks to BIGtoken, SRAX is well positioned to capitalize on the national and international regulatory changes aimed at protecting consumer data while opening up monetization opportunities for those consumers who opt into data sharing.

In addition to BIGtoken, SRAX has also developed SRAX IR, a product that uses behavioral data to help public companies identify developments within the supply and demand of their publicly traded stocks. SRAX IR helps stock companies reach potential investors based on current stock buyers’ behavior and trends, monitor shareholders’ behavior, uncover trends from buyers and sellers, analyze activity from market makers and track return on investment from investor relations programs.

Data monetization is a multibillion-dollar market. Global spending on business analytics and big data amounted to $166 billion in 2018 and is projected to reach $260 billion by 2022 (http://ibn.fm/BcMRZ). As consumers take back privacy and data ownership, supported by the regulatory changes worldwide, SRAX is poised to harness the rapid growth of this multibillion-dollar market.

For more information, visit the company’s website at www.SRAX.com

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in SRAX, Inc. SRAX | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) to Provide Patented DehydraTECH(TM) to Cannadips’ Cannabis Products in California and Across the US

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced that it has reached a new definitive agreement to provide its patented DehydraTECH(TM) technology to Cannadips’ cannabis products, both in its current California market and across the United States. According to the update, Lexaria’s DehydraTECH fast-acting, high-absorption technology is perfectly suited to improve consumer satisfaction and the dipping experience. Terpene-rich multi spectrum oils are base ingredients of Cannadips THC, and DehydraTECH is able to reduce throat irritation normally associated with some terpenes. Inferior products utilize less efficacious cannabis isolate without terpenes that lack the entourage effect derived from multi-spectrum oils in an attempt to get around this problem. “Lexaria is building a stronger relationship with the Cannadips brand and applying DehydraTECH to Cannadips cannabis represents our latest advance,” Lexaria Bioscience CEO Chris Bunka stated in the news release. “Our DehydraTECH technology empowers a scalable supply chain across state lines for our cannabis brand licensees. We are excited that Cannadips is interested in activating the Lexaria technology in additional key state markets that are either recreational or medical cannabis states, while preserving the brand rights as states come online through regulation.”

To view the full press release, visit http://ibn.fm/jj3JQ

About Lexaria Bioscience Corp.

Lexaria Bioscience is a global innovator in drug-delivery platforms. The company’s patented DehydraTECH drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time of onset and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Lexaria Bioscience Corp. (LXRP), MissionIRNewsBreaks | Leave a comment